Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era
•Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu A.•Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B.•Flu vaccine effectively prevents flu A hospital admission in child...
Saved in:
Published in | Vaccine Vol. 40; no. 22; pp. 3018 - 3026 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
11.05.2022
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu A.•Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B.•Flu vaccine effectively prevents flu A hospital admission in children aged 1–12.
We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.
The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons.
A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.
This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era. |
---|---|
AbstractList | Highlights•Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20. •Recent inactivated flu vaccine is effective in children and infants for flu A. •Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B. •Flu vaccine effectively prevents flu A hospital admission in children aged 1–12. BackgroundWe have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.MethodsThe overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons.ResultsA total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.ConclusionsThis is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era. We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.BACKGROUNDWe have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons.METHODSThe overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons.A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.RESULTSA total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.CONCLUSIONSThis is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era. •Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu A.•Vaccine effectiveness was highest among 1 to 2 year olds for flu A and flu B.•Flu vaccine effectively prevents flu A hospital admission in children aged 1–12. We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups. The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons. A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported. This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era. We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6–11 months) and older (6–15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups. The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6–11 months, 1–2, 3–5, 6–12, and 13–15 years old) with adjustments including influenza seasons. A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41–47], 63% [95 %CI, 51–72], and 37% [95 %CI, 32–42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55–65] and 52% [95 %CI, 41–61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported. This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era. We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups. The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons. A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported. This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era. |
Author | Mitamura, Keiko Oshima, Mio Shibata, Akimichi Kobayashi, Hisato Shimoyamada, Motoko Yamaguchi, Yoshio Kuramochi, Yuu Furuichi, Munehiro Nakata, Yuji Yaginuma, Mizuki Yoshida, Makoto Takahashi, Takao Maeda, Naonori Chiga, Michiko Kamimaki, Isamu Nishida, Mitsuhiro Shinjoh, Masayoshi Taguchi, Nobuhiko Ookawara, Ichiro Nogayama, Taisuke Narabayashi, Atsushi Yamada, Go Kobayashi, Ken Tsunematsu, Kenichiro |
Author_xml | – sequence: 1 givenname: Masayoshi orcidid: 0000-0002-6291-7186 surname: Shinjoh fullname: Shinjoh, Masayoshi email: m-shinjo@z2.keio.jp organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan – sequence: 2 givenname: Munehiro orcidid: 0000-0001-7742-1135 surname: Furuichi fullname: Furuichi, Munehiro email: furuichi-mm@keio.jp organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan – sequence: 3 givenname: Hisato orcidid: 0000-0002-1346-6729 surname: Kobayashi fullname: Kobayashi, Hisato email: hkobayashi1201@keio.jp organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan – sequence: 4 givenname: Yoshio surname: Yamaguchi fullname: Yamaguchi, Yoshio email: yoyamaguchitochigimc@gmail.com organization: Department of Clinical Research, Department of Infection and Allergy, National Hospital Organization Tochigi Medical Center, 1-10-37 Nakatomaturi, Utsunomiya-City, Tochigi 320-8580, Japan – sequence: 5 givenname: Naonori surname: Maeda fullname: Maeda, Naonori email: naonorimaeda27@gmail.com organization: Department of Pediatrics, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan – sequence: 6 givenname: Mizuki orcidid: 0000-0002-6335-360X surname: Yaginuma fullname: Yaginuma, Mizuki email: yaginumamizuki@keio.jp organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan – sequence: 7 givenname: Ken surname: Kobayashi fullname: Kobayashi, Ken email: le.petit.oeuf.26@gmail.com organization: Department of Pediatrics, Yokohama Municipal Citizen’s Hospital, 1-1 Mitsuzawanishimachi, Kanagawa-ku, Yokohama 221-0855, Kanagawa, Japan – sequence: 8 givenname: Taisuke surname: Nogayama fullname: Nogayama, Taisuke email: t.nogayama@keio.jp organization: Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka, Kanagawa 254-0065, Japan – sequence: 9 givenname: Michiko orcidid: 0000-0002-0346-9352 surname: Chiga fullname: Chiga, Michiko email: michiko_chiga@tmhp.jp organization: Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka, Toshima-ku, Tokyo 170-8476, Japan – sequence: 10 givenname: Mio orcidid: 0000-0001-9923-7347 surname: Oshima fullname: Oshima, Mio email: mio_ooshima@tmhp.jp organization: Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka, Toshima-ku, Tokyo 170-8476, Japan – sequence: 11 givenname: Yuu surname: Kuramochi fullname: Kuramochi, Yuu email: ykura123@gmail.com organization: Department of Pediatrics, Ota Memorial Hospital, 455-1 Ohshimacho, Ota City, Gunma 273-8585, Japan – sequence: 12 givenname: Go orcidid: 0000-0003-3122-2418 surname: Yamada fullname: Yamada, Go email: yamago.0414time@gmail.com organization: Department of Pediatrics, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa-shi, Chiba 272-8513, Japan – sequence: 13 givenname: Atsushi orcidid: 0000-0002-5274-8104 surname: Narabayashi fullname: Narabayashi, Atsushi email: naraba@keio.jp organization: Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan – sequence: 14 givenname: Ichiro orcidid: 0000-0002-4836-1732 surname: Ookawara fullname: Ookawara, Ichiro email: ichiro@szrc.org organization: Department of Pediatrics, Japanese Red Cross Shizuoka Hospital, 8-2 Outemachi, Aoi-ku, Shizuoka 420-0853, Japan – sequence: 15 givenname: Mitsuhiro orcidid: 0000-0003-2016-3598 surname: Nishida fullname: Nishida, Mitsuhiro email: mitsumed@outlook.jp organization: Department of Pediatrics, Shizuoka City Shimizu Hospital, 1231 Miyakami, Shimizu-ku, Shizuoka-shi, Shizuoka 424-8636, Japan – sequence: 16 givenname: Kenichiro surname: Tsunematsu fullname: Tsunematsu, Kenichiro email: ktsune0605@yahoo.co.jp organization: Department of Pediatrics, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0061, Japan – sequence: 17 givenname: Isamu surname: Kamimaki fullname: Kamimaki, Isamu email: kamimaki.isamu.bv@mail.hosp.go.jp organization: Department of Pediatrics, National Hospital Organization, Saitama Hospital, 2-1 Suwa, Wako-shi, Saitama 351-0102, Japan – sequence: 18 givenname: Motoko surname: Shimoyamada fullname: Shimoyamada, Motoko email: mochikodamochio@yahoo.co.jp organization: Department of Pediatrics, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 336-0911, Japan – sequence: 19 givenname: Makoto orcidid: 0000-0002-2846-2069 surname: Yoshida fullname: Yoshida, Makoto email: yoshimako0731@yahoo.co.jp organization: Department of Pediatrics, Sano Kosei General Hospital, 1728 Horigome-chou, Sano-city, Tochigi 327-8511, Japan – sequence: 20 givenname: Akimichi surname: Shibata fullname: Shibata, Akimichi email: helloakimichi@yahoo.co.jp organization: Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, 284-1 Yobe-cho, Ashikaga, Tochigi 326-0843, Japan – sequence: 21 givenname: Yuji surname: Nakata fullname: Nakata, Yuji email: hihiyuji@gmail.com organization: Department of Pediatrics, Nippon Koukan Hospital, 1-2-1Koukan-Dori, Kawasaki, Kanagawa 210-0852, Japan – sequence: 22 givenname: Nobuhiko surname: Taguchi fullname: Taguchi, Nobuhiko email: n-taguchi@keiyu-hospital.com organization: Department of Pediatrics, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa 220-8581, Japan – sequence: 23 givenname: Keiko surname: Mitamura fullname: Mitamura, Keiko email: mitamurakeiko77@gmail.com organization: Department of Pediatrics, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo 110-8645, Japan – sequence: 24 givenname: Takao orcidid: 0000-0001-9922-1775 surname: Takahashi fullname: Takahashi, Takao email: ttakahashi@keio.jp organization: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35450780$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUltv0zAYtdAQ6wY_AWSJF15SfEniRIgh1HGZNGkPDMSb5TifW5fULnZSqfsD_G0c2k1QCW0vvp5z_Pk75wQdOe8AoeeUTCmh5evldKO0tg6mjDA2JfmUcP4ITWgleMYKWh2hCWFlnuWUfD9GJzEuCSEFp_UTdMyLvCCiIhP06zqAayO2DoMxoHu7AQcxYm_SmRr3qoc2rU03gLtReP_syNAL27WJj5stVnPA8-CH9R-tCEkmjSp6lw5WK2ht0um2uAHjA-B-AXh29e3iPKM1hqCeosdGdRGe7edT9PXjh-vZ5-zy6tPF7P1lpgXhfcZMTTlThoNqdW2gAVI0lSBNuhBtCaVgojVAeVtXaVJVS4SomkYxqhShhp-is53uemhSURpcH1Qn18GuVNhKr6z898bZhZz7jazquuCMJYFXe4Hgfw4Qe7myUUPXKQd-iJKVJU19p2X9AGiRs7rkhUjQlwfQpR-CS50YUYLTIi9JQr34u_i7qm_tTIA3O4AOPsYARmrbq9768S-2k5TIMTxyKfcuyjE8kuQyhSexiwP27QP38d7teJCM21gIMmoLTifPQ0qUbL29V-HsQEF31lmtuh-whXjXCypj4sgvY7DHXDNGSJ7Xoytv_y_wgAJ-A3EnDSw |
CitedBy_id | crossref_primary_10_1097_INF_0000000000004139 crossref_primary_10_1016_j_vaccine_2024_126241 crossref_primary_10_1016_j_vaccine_2023_06_082 crossref_primary_10_36290_ped_2022_067 |
Cites_doi | 10.2807/1560-7917.ES.2020.25.10.2000153 10.1016/j.vaccine.2017.07.003 10.1016/j.vaccine.2021.05.049 10.1016/j.celrep.2019.12.063 10.1586/14760584.2014.951036 10.1371/journal.pone.0136539 10.1371/journal.pone.0249005 10.1086/432938 10.1016/j.vaccine.2019.09.086 10.1093/infdis/jiab273 10.1016/j.vaccine.2018.07.065 10.1001/jamapediatrics.2020.0372 10.1016/j.vaccine.2019.05.090 10.1016/j.jiac.2019.08.015 10.1111/irv.12626 10.2807/1560-7917.ES.2021.26.29.2100706 10.1007/s00431-018-3145-7 10.1038/s41467-021-23440-1 10.1016/j.ijid.2020.07.032 10.1016/j.vaccine.2018.01.024 10.1016/j.jvacx.2019.100011 10.1016/j.jviromet.2013.08.018 10.1093/infdis/jiaa685 10.1093/infdis/jiaa800 10.1016/j.jiac.2021.08.020 10.1093/cid/cix312 10.15585/mmwr.rr6908a1 10.1093/cid/cir336 10.1016/j.vaccine.2020.12.012 10.2807/1560-7917.ES.2020.25.7.2000103 10.1016/j.vaccine.2010.12.049 10.7326/M17-0848 10.15585/mmwr.rr7005a1 10.1371/journal.pone.0231217 10.3390/vaccines9050415 10.1016/j.vaccine.2015.01.069 10.2807/1560-7917.ES.2019.24.4.1900055 10.1542/peds.2020-024588 |
ContentType | Journal Article |
Copyright | 2022 Elsevier Ltd Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. 2022. Elsevier Ltd 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. – notice: 2022. Elsevier Ltd – notice: 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
DOI | 10.1016/j.vaccine.2022.04.033 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | Research Library Prep MEDLINE - Academic AGRICOLA MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 3026 |
ExternalDocumentID | PMC8995322 35450780 10_1016_j_vaccine_2022_04_033 S0264410X22004492 1_s2_0_S0264410X22004492 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States--US Japan |
GeographicLocations_xml | – name: United States--US – name: Japan |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP CITATION CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
ID | FETCH-LOGICAL-c703t-2f9132af3eadc9febe05b870b2f97d6e6727dfe13d98fe1a8d0778bba21aa01f3 |
IEDL.DBID | .~1 |
ISSN | 0264-410X 1873-2518 |
IngestDate | Thu Aug 21 13:39:50 EDT 2025 Fri Jul 11 17:31:24 EDT 2025 Tue Aug 05 09:47:14 EDT 2025 Wed Aug 13 09:23:22 EDT 2025 Thu Apr 03 07:08:39 EDT 2025 Tue Jul 01 01:07:06 EDT 2025 Thu Apr 24 22:53:50 EDT 2025 Wed Jun 26 17:48:47 EDT 2024 Tue Feb 25 20:05:39 EST 2025 Tue Aug 26 16:34:50 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Keywords | Vaccine Children Test-negative design Influenza COVID-19 era Vaccine effectiveness |
Language | English |
License | Copyright © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c703t-2f9132af3eadc9febe05b870b2f97d6e6727dfe13d98fe1a8d0778bba21aa01f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-2016-3598 0000-0002-6335-360X 0000-0002-5274-8104 0000-0002-4836-1732 0000-0002-6291-7186 0000-0001-9923-7347 0000-0001-7742-1135 0000-0002-0346-9352 0000-0003-3122-2418 0000-0001-9922-1775 0000-0002-1346-6729 0000-0002-2846-2069 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8995322 |
PMID | 35450780 |
PQID | 2657315460 |
PQPubID | 105530 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8995322 proquest_miscellaneous_2661026169 proquest_miscellaneous_2654296357 proquest_journals_2657315460 pubmed_primary_35450780 crossref_citationtrail_10_1016_j_vaccine_2022_04_033 crossref_primary_10_1016_j_vaccine_2022_04_033 elsevier_sciencedirect_doi_10_1016_j_vaccine_2022_04_033 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X22004492 elsevier_clinicalkey_doi_10_1016_j_vaccine_2022_04_033 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-05-11 |
PublicationDateYYYYMMDD | 2022-05-11 |
PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-11 day: 11 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Kidlington |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2022 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Shinjoh, Sugaya, Yamaguchi, Tomidokoro, Sekiguchi, Mitamura (b0045) 2015; 10 Feng, Zhang, Wang, Xie, Peng, Zheng (b0175) 2021; 12 Kowalska M, Niewiadomska E, Barański K, Kaleta-Pilarska A, Brożek G, Zejda JE. Association between influenza vaccination and positive SARS-CoV-2 IgG and IgM tests in the general population of Katowice Region, Poland. Vaccines (Basel) 2021; 9. https://doi.org10.3390/vaccines9050415. Martin, Cheng, Petrie, Alyanak, Gaglani, Middleton (b0095) 2021; 223 World Health Organization. South-East Asia Region of WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS) 15. National Institute of Infectious Diseases. Information on epidemiology of influenza (In Japanese) Shinjoh, Sugaya, Yamaguchi, Ookawara, Nakata, Narabayashi (b0035) 2021; 16 Fink, Orlova-Fink, Schindler, Grisi, Ferrer, Daubenberger (b0210) 2020 Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, et al. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Euro Surveill 2020; 25. Grohskopf, Alyanak, Ferdinands, Broder, Blanton, Talbot (b0025) 2021; 70 Sugaya, Shinjoh, Nakata, Tsunematsu, Yamaguchi, Komiyama (b0060) 2018; 36 Grohskopf, Alyanak, Broder, Blanton, Fry, Jernigan (b0040) 2020; 69 Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Euro Surveill 2020; 25. https://doi.org10.2807/1560-7917.Es.2020.25.10.2000153. Cowling, Wu, Lo, Chan, Chan, Fang (b0120) 2017; 65 Sugaya, Shinjoh, Kawakami, Yamaguchi, Yoshida, Baba (b0050) 2016 Horns F, Dekker CL, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Rep 2020; 30:905-13.e6. https://doi.org10.1016/j.celrep.2019.12.063. Fukushima, Hirota (b0250) 2017; 35 6. National Institute of Infectious Diseases. Figures for National Epidemiological Surveillance of Infectious Disease (NESVPD) (In Japanese) Feldstein, Ferdinands, Self, Randolph, Aboodi, Baughman (b0255) 2021; 224 Chung, Flannery, Gaglani, Smith, Reis, Hickey (b0130) 2020; 174 Ujiie, Tsuzuki, Nakamoto, Iwamoto (b0195) 2021; 27 Shinjoh, Sugaya, Furuichi, Araki, Maeda, Isshiki (b0065) 2019; 37 Yoshihara, Le, Toizumi, Nguyen, Vo, Odagiri (b0115) 2019; 13 Shinjoh, Furuichi, Narabayashi, Kamei, Yoshida, Takahashi (b0070) 2021 . Katayose, Hosoya, Haneda, Yamaguchi, Kawasaki, Sato (b0105) 2011; 29 Mitamura, Shimizu, Yamazaki, Ichikawa, Abe, Yasumi (b0080) 2020; 26 National Institute of Infectious Diseases. Preliminary report of isolated virus, Infectious Agents Surveillance Report (IASR) (In Japanese) Wall, Patel, Chung, Lee, Dawood (b0125) 2021 ; = Sohn, Choi, Choi, Choe, Kim, Kim (b0235) 2020; 99 Jackson, Rothman (b0230) 2015; 33 Kimiya, Shinjoh, Anzo, Takahashi, Sekiguchi, Sugaya (b0135) 2018; 177 Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N, Brosh-Nissimov T. Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro Surveill 2021; 26. Chon, Saito, Hibino, Yagami, Dapat, Odagiri (b0240) 2019; 1 Friedman, Renaud, Hines, Winter, Bolotin, Johnstone (b0020) 2019; 37 Yokohama City Institute of Public Health. Analysis of isolated influenza virus in Yokohama City in 2019/20 season (In Japanese) Sugaya (b0015) 2014; 13 [accessed 20 September 2021]. National Institute of Infectious Diseases. Reactivity between isolated A(H1N1)pdm virus and antiserum in the 2019/20 season in Japan (In Japanese) Merckx, Wali, Schiller, Caya, Gore, Chartrand (b0220) 2017; 167 World Health Organization. WHO public health research agenda for influenza: Optimizing treatment of patients, 2017 update. Thangarajah, Malo, Field, Andrews, Ware, Lambert (b0110) 2021; 39 Recommendations for prevention and control of influenza in children, 2020-2021. Pediatrics 2020; 146. Shinjoh, Sugaya, Yamaguchi, Iibuchi, Kamimaki, Goto (b0055) 2018; 36 Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill 2019; 24. Zipfel, Colizza, Bansal (b0170) 2021; 39 Seki, Oda, Sugaya (b0090) 2020; 15 Kawai, Nanri, Ban, Inokuchi, Tanaka, Tokumura (b0010) 2011; 53 Tenforde, Talbot, Trabue, Gaglani, McNeal, Monto (b0100) 2021; 224 Sugaya, Takeuchi (b0005) 2005; 41 World Health Organization. Southern hemisphere. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS) Patwardhan, Ohler (b0200) 2021; 13 Mitamura, Shimizu, Yamazaki, Ichikawa, Nagai, Katada (b0085) 2013; 194 10.1016/j.vaccine.2022.04.033_b0155 Fukushima (10.1016/j.vaccine.2022.04.033_b0250) 2017; 35 Chung (10.1016/j.vaccine.2022.04.033_b0130) 2020; 174 Merckx (10.1016/j.vaccine.2022.04.033_b0220) 2017; 167 Kawai (10.1016/j.vaccine.2022.04.033_b0010) 2011; 53 Shinjoh (10.1016/j.vaccine.2022.04.033_b0055) 2018; 36 Wall (10.1016/j.vaccine.2022.04.033_b0125) 2021 10.1016/j.vaccine.2022.04.033_b0160 Martin (10.1016/j.vaccine.2022.04.033_b0095) 2021; 223 Thangarajah (10.1016/j.vaccine.2022.04.033_b0110) 2021; 39 10.1016/j.vaccine.2022.04.033_b0205 Kimiya (10.1016/j.vaccine.2022.04.033_b0135) 2018; 177 10.1016/j.vaccine.2022.04.033_b0165 Sugaya (10.1016/j.vaccine.2022.04.033_b0060) 2018; 36 10.1016/j.vaccine.2022.04.033_b0245 Shinjoh (10.1016/j.vaccine.2022.04.033_b0065) 2019; 37 Sugaya (10.1016/j.vaccine.2022.04.033_b0015) 2014; 13 Friedman (10.1016/j.vaccine.2022.04.033_b0020) 2019; 37 Jackson (10.1016/j.vaccine.2022.04.033_b0230) 2015; 33 Yoshihara (10.1016/j.vaccine.2022.04.033_b0115) 2019; 13 Sugaya (10.1016/j.vaccine.2022.04.033_b0005) 2005; 41 Seki (10.1016/j.vaccine.2022.04.033_b0090) 2020; 15 Grohskopf (10.1016/j.vaccine.2022.04.033_b0040) 2020; 69 Mitamura (10.1016/j.vaccine.2022.04.033_b0085) 2013; 194 Cowling (10.1016/j.vaccine.2022.04.033_b0120) 2017; 65 Mitamura (10.1016/j.vaccine.2022.04.033_b0080) 2020; 26 Sugaya (10.1016/j.vaccine.2022.04.033_b0050) 2016 Katayose (10.1016/j.vaccine.2022.04.033_b0105) 2011; 29 Fink (10.1016/j.vaccine.2022.04.033_b0210) 2020 Sohn (10.1016/j.vaccine.2022.04.033_b0235) 2020; 99 Shinjoh (10.1016/j.vaccine.2022.04.033_b0045) 2015; 10 10.1016/j.vaccine.2022.04.033_b0215 Patwardhan (10.1016/j.vaccine.2022.04.033_b0200) 2021; 13 10.1016/j.vaccine.2022.04.033_b0140 10.1016/j.vaccine.2022.04.033_b0185 10.1016/j.vaccine.2022.04.033_b0180 Shinjoh (10.1016/j.vaccine.2022.04.033_b0035) 2021; 16 Feng (10.1016/j.vaccine.2022.04.033_b0175) 2021; 12 Feldstein (10.1016/j.vaccine.2022.04.033_b0255) 2021; 224 Zipfel (10.1016/j.vaccine.2022.04.033_b0170) 2021; 39 Tenforde (10.1016/j.vaccine.2022.04.033_b0100) 2021; 224 Ujiie (10.1016/j.vaccine.2022.04.033_b0195) 2021; 27 Shinjoh (10.1016/j.vaccine.2022.04.033_b0070) 2021 10.1016/j.vaccine.2022.04.033_b0225 10.1016/j.vaccine.2022.04.033_b0145 10.1016/j.vaccine.2022.04.033_b0150 10.1016/j.vaccine.2022.04.033_b0030 10.1016/j.vaccine.2022.04.033_b0075 10.1016/j.vaccine.2022.04.033_b0190 Grohskopf (10.1016/j.vaccine.2022.04.033_b0025) 2021; 70 Chon (10.1016/j.vaccine.2022.04.033_b0240) 2019; 1 |
References_xml | – reference: Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Euro Surveill 2020; 25. https://doi.org10.2807/1560-7917.Es.2020.25.10.2000153. – volume: 37 start-page: 4047 year: 2019 end-page: 4054 ident: b0065 article-title: Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013–18 publication-title: Vaccine – volume: 26 start-page: 216 year: 2020 end-page: 221 ident: b0080 article-title: Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comparison with currently available tests publication-title: J Infect Chemother – volume: 224 start-page: 813 year: 2021 end-page: 820 ident: b0100 article-title: Influenza vaccine effectiveness against hospitalization in the United States, 2019–2020 publication-title: J Infect Dis – volume: 70 start-page: 1 year: 2021 end-page: 28 ident: b0025 article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season publication-title: MMWR Recomm Rep – volume: 16 year: 2021 ident: b0035 article-title: Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season publication-title: PLoS ONE – volume: 29 start-page: 1844 year: 2011 end-page: 1849 ident: b0105 article-title: The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons publication-title: Vaccine – reference: ; – volume: 69 start-page: 1 year: 2020 end-page: 24 ident: b0040 article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020–21 Influenza Season publication-title: MMWR Recomm Rep – volume: 167 start-page: 394 year: 2017 end-page: 409 ident: b0220 article-title: Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: A systematic review and meta-analysis publication-title: Ann Intern Med – volume: 223 start-page: 2062 year: 2021 end-page: 2071 ident: b0095 article-title: Low influenza vaccine effectiveness against A(H3N2)-associated hospitalizations in 2016–2017 and 2017–2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) publication-title: J Infect Dis – volume: 13 start-page: 1563 year: 2014 end-page: 1570 ident: b0015 article-title: A review of the indirect protection of younger children and the elderly through a mass influenza vaccination program in Japan publication-title: Expert Rev Vaccines – reference: [accessed 20 September 2021]. – volume: 99 start-page: 199 year: 2020 end-page: 203 ident: b0235 article-title: Effectiveness of trivalent inactivated influenza vaccines in children during 2017–2018 season in Korea: Comparison of test-negative analysis by rapid and RT-PCR influenza tests publication-title: Int J Infect Dis – volume: 36 start-page: 5510 year: 2018 end-page: 5518 ident: b0055 article-title: Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season publication-title: Vaccine – volume: 33 start-page: 1313 year: 2015 end-page: 1316 ident: b0230 article-title: Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness publication-title: Vaccine – reference: =; – reference: National Institute of Infectious Diseases. Preliminary report of isolated virus, Infectious Agents Surveillance Report (IASR) (In Japanese), – volume: 174 start-page: 705 year: 2020 end-page: 713 ident: b0130 article-title: Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness publication-title: JAMA Pediatr – volume: 37 start-page: 7213 year: 2019 end-page: 7232 ident: b0020 article-title: Exploring indirect protection associated with influenza immunization - A systematic review of the literature publication-title: Vaccine – reference: Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill 2019; 24. – start-page: 21 year: 2016 ident: b0050 article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season publication-title: Japan Euro Surveill – year: 2021 ident: b0070 article-title: Risk factors in pediatric hospitalization for influenza A and B during the seven seasons immediately before the COVID-19 era in Japan publication-title: J Infect Chemother – volume: 39 start-page: 3645 year: 2021 end-page: 3648 ident: b0170 article-title: The missing season: The impacts of the COVID-19 pandemic on influenza publication-title: Vaccine – year: 2020 ident: b0210 article-title: Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ publication-title: Evid Based Med – volume: 27 year: 2021 ident: b0195 article-title: Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo publication-title: Japan Emerg Infect Dis – volume: 36 start-page: 1063 year: 2018 end-page: 1071 ident: b0060 article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016 publication-title: Vaccine – reference: World Health Organization. South-East Asia Region of WHO. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS), – reference: 6. National Institute of Infectious Diseases. Figures for National Epidemiological Surveillance of Infectious Disease (NESVPD) (In Japanese), – reference: World Health Organization. WHO public health research agenda for influenza: Optimizing treatment of patients, 2017 update., – reference: Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, et al. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Euro Surveill 2020; 25. – reference: Kowalska M, Niewiadomska E, Barański K, Kaleta-Pilarska A, Brożek G, Zejda JE. Association between influenza vaccination and positive SARS-CoV-2 IgG and IgM tests in the general population of Katowice Region, Poland. Vaccines (Basel) 2021; 9. https://doi.org10.3390/vaccines9050415. – volume: 15 year: 2020 ident: b0090 article-title: Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness publication-title: PLoS ONE – volume: 39 start-page: 729 year: 2021 end-page: 737 ident: b0110 article-title: Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018 publication-title: Vaccine – reference: Recommendations for prevention and control of influenza in children, 2020-2021. Pediatrics 2020; 146. – reference: Horns F, Dekker CL, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Rep 2020; 30:905-13.e6. https://doi.org10.1016/j.celrep.2019.12.063. – volume: 65 start-page: 300 year: 2017 end-page: 307 ident: b0120 article-title: Population-based pediatric hospitalization burden of lineage-specific influenza B in Hong Kong, 2004–2014 publication-title: Clin Infect Dis – reference: National Institute of Infectious Diseases. Reactivity between isolated A(H1N1)pdm virus and antiserum in the 2019/20 season in Japan (In Japanese) – volume: 194 start-page: 123 year: 2013 end-page: 128 ident: b0085 article-title: Clinical evaluation of highly sensitive silver amplification immunochromatography systems for rapid diagnosis of influenza publication-title: J Virol Methods – volume: 13 start-page: 248 year: 2019 end-page: 261 ident: b0115 article-title: Influenza B associated paediatric acute respiratory infection hospitalization in central Vietnam publication-title: Influenza Other Respir Viruses – volume: 13 year: 2021 ident: b0200 article-title: The flu vaccination may have a protective effect on the course of COVID-19 in the pediatric population: When does severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) meet influenza? publication-title: Cureus – volume: 41 start-page: 939 year: 2005 end-page: 947 ident: b0005 article-title: Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan publication-title: Clin Infect Dis – reference: . – volume: 53 start-page: 130 year: 2011 end-page: 136 ident: b0010 article-title: Influenza vaccination of schoolchildren and influenza outbreaks in a school publication-title: Clin Infect Dis – reference: Yokohama City Institute of Public Health. Analysis of isolated influenza virus in Yokohama City in 2019/20 season (In Japanese), – volume: 10 year: 2015 ident: b0045 article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results publication-title: PLoS ONE – start-page: 147 year: 2021 ident: b0125 article-title: Antibody response and protection after receipt of inactivated influenza vaccine: A systematic review publication-title: Pediatrics – volume: 12 start-page: 3249 year: 2021 ident: b0175 article-title: Impact of COVID-19 outbreaks and interventions on influenza in China and the United States publication-title: Nat Commun – volume: 1 year: 2019 ident: b0240 article-title: Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015–2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation publication-title: Vaccine X – reference: World Health Organization. Southern hemisphere. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS), – volume: 35 start-page: 4796 year: 2017 end-page: 4800 ident: b0250 article-title: Basic principles of test-negative design in evaluating influenza vaccine effectiveness publication-title: Vaccine – volume: 224 start-page: 2035 year: 2021 end-page: 2042 ident: b0255 article-title: Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates publication-title: J Infect Dis – volume: 177 start-page: 1009 year: 2018 end-page: 1017 ident: b0135 article-title: Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design publication-title: Eur J Pediatr – reference: Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N, Brosh-Nissimov T. Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro Surveill 2021; 26. – reference: 15. National Institute of Infectious Diseases. Information on epidemiology of influenza (In Japanese) – ident: 10.1016/j.vaccine.2022.04.033_b0140 doi: 10.2807/1560-7917.ES.2020.25.10.2000153 – volume: 35 start-page: 4796 year: 2017 ident: 10.1016/j.vaccine.2022.04.033_b0250 article-title: Basic principles of test-negative design in evaluating influenza vaccine effectiveness publication-title: Vaccine doi: 10.1016/j.vaccine.2017.07.003 – volume: 39 start-page: 3645 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0170 article-title: The missing season: The impacts of the COVID-19 pandemic on influenza publication-title: Vaccine doi: 10.1016/j.vaccine.2021.05.049 – ident: 10.1016/j.vaccine.2022.04.033_b0215 doi: 10.1016/j.celrep.2019.12.063 – volume: 13 start-page: 1563 year: 2014 ident: 10.1016/j.vaccine.2022.04.033_b0015 article-title: A review of the indirect protection of younger children and the elderly through a mass influenza vaccination program in Japan publication-title: Expert Rev Vaccines doi: 10.1586/14760584.2014.951036 – volume: 10 year: 2015 ident: 10.1016/j.vaccine.2022.04.033_b0045 article-title: Effectiveness of trivalent inactivated influenza vaccine in children estimated by a test-negative case-control design study based on influenza rapid diagnostic test results publication-title: PLoS ONE doi: 10.1371/journal.pone.0136539 – ident: 10.1016/j.vaccine.2022.04.033_b0155 – volume: 16 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0035 article-title: Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season publication-title: PLoS ONE doi: 10.1371/journal.pone.0249005 – ident: 10.1016/j.vaccine.2022.04.033_b0225 – ident: 10.1016/j.vaccine.2022.04.033_b0160 – volume: 41 start-page: 939 year: 2005 ident: 10.1016/j.vaccine.2022.04.033_b0005 article-title: Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan publication-title: Clin Infect Dis doi: 10.1086/432938 – volume: 37 start-page: 7213 year: 2019 ident: 10.1016/j.vaccine.2022.04.033_b0020 article-title: Exploring indirect protection associated with influenza immunization - A systematic review of the literature publication-title: Vaccine doi: 10.1016/j.vaccine.2019.09.086 – volume: 224 start-page: 2035 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0255 article-title: Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates publication-title: J Infect Dis doi: 10.1093/infdis/jiab273 – volume: 36 start-page: 5510 year: 2018 ident: 10.1016/j.vaccine.2022.04.033_b0055 article-title: Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season publication-title: Vaccine doi: 10.1016/j.vaccine.2018.07.065 – volume: 174 start-page: 705 year: 2020 ident: 10.1016/j.vaccine.2022.04.033_b0130 article-title: Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2020.0372 – volume: 37 start-page: 4047 year: 2019 ident: 10.1016/j.vaccine.2022.04.033_b0065 article-title: Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013–18 publication-title: Vaccine doi: 10.1016/j.vaccine.2019.05.090 – volume: 26 start-page: 216 year: 2020 ident: 10.1016/j.vaccine.2022.04.033_b0080 article-title: Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comparison with currently available tests publication-title: J Infect Chemother doi: 10.1016/j.jiac.2019.08.015 – volume: 13 start-page: 248 year: 2019 ident: 10.1016/j.vaccine.2022.04.033_b0115 article-title: Influenza B associated paediatric acute respiratory infection hospitalization in central Vietnam publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12626 – ident: 10.1016/j.vaccine.2022.04.033_b0190 doi: 10.2807/1560-7917.ES.2021.26.29.2100706 – volume: 177 start-page: 1009 year: 2018 ident: 10.1016/j.vaccine.2022.04.033_b0135 article-title: Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design publication-title: Eur J Pediatr doi: 10.1007/s00431-018-3145-7 – volume: 12 start-page: 3249 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0175 article-title: Impact of COVID-19 outbreaks and interventions on influenza in China and the United States publication-title: Nat Commun doi: 10.1038/s41467-021-23440-1 – volume: 99 start-page: 199 year: 2020 ident: 10.1016/j.vaccine.2022.04.033_b0235 article-title: Effectiveness of trivalent inactivated influenza vaccines in children during 2017–2018 season in Korea: Comparison of test-negative analysis by rapid and RT-PCR influenza tests publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2020.07.032 – volume: 36 start-page: 1063 year: 2018 ident: 10.1016/j.vaccine.2022.04.033_b0060 article-title: Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013–2016 publication-title: Vaccine doi: 10.1016/j.vaccine.2018.01.024 – ident: 10.1016/j.vaccine.2022.04.033_b0165 – volume: 1 year: 2019 ident: 10.1016/j.vaccine.2022.04.033_b0240 article-title: Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015–2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation publication-title: Vaccine X doi: 10.1016/j.jvacx.2019.100011 – volume: 194 start-page: 123 year: 2013 ident: 10.1016/j.vaccine.2022.04.033_b0085 article-title: Clinical evaluation of highly sensitive silver amplification immunochromatography systems for rapid diagnosis of influenza publication-title: J Virol Methods doi: 10.1016/j.jviromet.2013.08.018 – start-page: 147 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0125 article-title: Antibody response and protection after receipt of inactivated influenza vaccine: A systematic review publication-title: Pediatrics – volume: 223 start-page: 2062 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0095 article-title: Low influenza vaccine effectiveness against A(H3N2)-associated hospitalizations in 2016–2017 and 2017–2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) publication-title: J Infect Dis doi: 10.1093/infdis/jiaa685 – volume: 224 start-page: 813 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0100 article-title: Influenza vaccine effectiveness against hospitalization in the United States, 2019–2020 publication-title: J Infect Dis doi: 10.1093/infdis/jiaa800 – year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0070 article-title: Risk factors in pediatric hospitalization for influenza A and B during the seven seasons immediately before the COVID-19 era in Japan publication-title: J Infect Chemother doi: 10.1016/j.jiac.2021.08.020 – volume: 65 start-page: 300 year: 2017 ident: 10.1016/j.vaccine.2022.04.033_b0120 article-title: Population-based pediatric hospitalization burden of lineage-specific influenza B in Hong Kong, 2004–2014 publication-title: Clin Infect Dis doi: 10.1093/cid/cix312 – volume: 69 start-page: 1 year: 2020 ident: 10.1016/j.vaccine.2022.04.033_b0040 article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020–21 Influenza Season publication-title: MMWR Recomm Rep doi: 10.15585/mmwr.rr6908a1 – ident: 10.1016/j.vaccine.2022.04.033_b0185 – volume: 53 start-page: 130 year: 2011 ident: 10.1016/j.vaccine.2022.04.033_b0010 article-title: Influenza vaccination of schoolchildren and influenza outbreaks in a school publication-title: Clin Infect Dis doi: 10.1093/cid/cir336 – year: 2020 ident: 10.1016/j.vaccine.2022.04.033_b0210 article-title: Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ publication-title: Evid Based Med – volume: 39 start-page: 729 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0110 article-title: Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018 publication-title: Vaccine doi: 10.1016/j.vaccine.2020.12.012 – ident: 10.1016/j.vaccine.2022.04.033_b0145 doi: 10.2807/1560-7917.ES.2020.25.7.2000103 – volume: 29 start-page: 1844 year: 2011 ident: 10.1016/j.vaccine.2022.04.033_b0105 article-title: The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons publication-title: Vaccine doi: 10.1016/j.vaccine.2010.12.049 – volume: 167 start-page: 394 year: 2017 ident: 10.1016/j.vaccine.2022.04.033_b0220 article-title: Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: A systematic review and meta-analysis publication-title: Ann Intern Med doi: 10.7326/M17-0848 – ident: 10.1016/j.vaccine.2022.04.033_b0030 – volume: 70 start-page: 1 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0025 article-title: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season publication-title: MMWR Recomm Rep doi: 10.15585/mmwr.rr7005a1 – volume: 13 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0200 article-title: The flu vaccination may have a protective effect on the course of COVID-19 in the pediatric population: When does severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) meet influenza? publication-title: Cureus – volume: 15 year: 2020 ident: 10.1016/j.vaccine.2022.04.033_b0090 article-title: Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness publication-title: PLoS ONE doi: 10.1371/journal.pone.0231217 – ident: 10.1016/j.vaccine.2022.04.033_b0205 doi: 10.3390/vaccines9050415 – volume: 27 year: 2021 ident: 10.1016/j.vaccine.2022.04.033_b0195 article-title: Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo publication-title: Japan Emerg Infect Dis – volume: 33 start-page: 1313 year: 2015 ident: 10.1016/j.vaccine.2022.04.033_b0230 article-title: Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness publication-title: Vaccine doi: 10.1016/j.vaccine.2015.01.069 – ident: 10.1016/j.vaccine.2022.04.033_b0150 doi: 10.2807/1560-7917.ES.2019.24.4.1900055 – ident: 10.1016/j.vaccine.2022.04.033_b0075 – start-page: 21 year: 2016 ident: 10.1016/j.vaccine.2022.04.033_b0050 article-title: Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season publication-title: Japan Euro Surveill – ident: 10.1016/j.vaccine.2022.04.033_b0245 doi: 10.1542/peds.2020-024588 – ident: 10.1016/j.vaccine.2022.04.033_b0180 |
SSID | ssj0005319 |
Score | 2.4070482 |
Snippet | •Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20.•Recent inactivated flu vaccine is effective in children and infants for flu... Highlights•Flu vaccine effectiveness for children was analyzed for 2013/14 to 2019/20. •Recent inactivated flu vaccine is effective in children and infants for... We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons.... BackgroundWe have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19... We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons.... |
SourceID | pubmedcentral proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 3018 |
SubjectTerms | Adolescent Age Age groups Allergy and Immunology Case-Control Studies Child Child, Preschool Children confidence interval Confidence intervals Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 era COVID-19 infection COVID-19 vaccines Deactivation Disease transmission Hospitals Humans Immunization Infant Influenza Influenza A Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza B Influenza B virus Influenza Vaccines Influenza, Human - epidemiology Influenza, Human - prevention & control Maternal & child health Outpatient care facilities Patients Seasons Software Test-negative design Vaccination Vaccine Vaccine effectiveness Vaccine efficacy Vaccines Vaccines, Inactivated Viral diseases |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagCNQLguUVKMhIqKemtfNyfEKoUBWkQiXaam-WHTtiq5JtybbS8gf428w4TkJ5tJx2tfas43g88409D0JemdzaMpEmtlqmcaaLKgY7RMQ6N4XQFRdGY-zw3sdi9zD7MM2n4cCtDW6VvUz0gtrOKzwj30qKXKSg7wv2-vQsxqpReLsaSmjcJLcwdRlytZiK0cUj9YU9wMzI4oyz6RjBs3W8eaErvLoGEzFJfLbTNP2XbvoTe_7uQvmLTtq5R-4GMEnfdKt_n9xwzYTc7spLLifkzl64OJ-Q9f0uRfVygx6MEVftBl2n-2PyaqCZHKF_jA_SpT35A_Kjc52ls4Z2DiBBRtJ5Db9hbMQFYFYL333Jk--ahnkjRR8vTs2SgvSiPpDE_1eL6aMoHlMC79PZVx_GsnAnS2ocgGlHAZ3S7U9H79_GXFJ47IfkcOfdwfZuHEo4xBWIkkWc1BLMXV2nwLCVrIFjWG5ARBhoELZweA9sa8dTK0v40KVlQpTG6IRrzXidPiIrzbxxTwjVmQNLQFvmkgqNUiO55SIFAFMUgtUuIlm_eKoK-c2xzMaJ6h3ZjlWYu8I1VyxTsOYR2RzITrsEH9cRFD1nqD56FeStAhV0HaH4G6Frg9RoFVctdFafmUepbJqgCMtkEpFyoAzAqAM8_zPoWs-8ahhn3EsReTk0g1zByyLduPm57wNQBbMVXtUHwDeY4IWMyONuPwzvMAVoDvATRhCXdsrQAfOaX25pZl98fvNSyhz0zNOrH_0ZWcV5oicH52tkZfHt3D0HgLgwL7wU-AlRsGf9 priority: 102 providerName: ProQuest |
Title | Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X22004492 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X22004492 https://dx.doi.org/10.1016/j.vaccine.2022.04.033 https://www.ncbi.nlm.nih.gov/pubmed/35450780 https://www.proquest.com/docview/2657315460 https://www.proquest.com/docview/2654296357 https://www.proquest.com/docview/2661026169 https://pubmed.ncbi.nlm.nih.gov/PMC8995322 |
Volume | 40 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemIRAvCMpXYCAjoT0tbZwvx4-jbOpAKxVsU98sO3FEppFOtJtUHnjl3-bOcdKVAUO8JGl8F8fx-fy7-u5MyGudFEUWCu0XSkR-rNLcBzuE-yrRKVc541ph7PDhOB0dx--myXSDDNtYGHSrdLq_0elWW7s7A_c1B-dVNfgU2Lk8mIbY0bFAPRzHHKW8__2Km0dkN_dAYh-pV1E8g9P-pcpx-RrMxDC0GU-j6E_z03X8-asb5ZV5af8-uecAJd1t3vkB2TB1j9xutphc9sidQ7d43iPbkyZN9XKHHq2iruY7dJtOVgmsgad3gj4yNlCXtuwPyY_GfZZWNW2cQJyepLMS7mF8xCXg1gKu7bYn3xR17UaONmac6iUFDUZtMIl91hxTSFH8qxLkn1ZfbCjLwpwtqTYAqA0FhEqHH04O3vpMUHjtR-R4f-9oOPLdNg5-Dupk4YelAJNXlREIbS5KkJog0aAmNBTwIjW4FlyUhkWFyOCksiLgPNNahUypgJXRY7JZz2rzlFAVG7AGVBGYMEfDVAtWMB4BiElTHpTGI3HbeTJ3Oc5xq40z2TqznUrXdol9LoNYQp97pN-xnTdJPm5iSFvJkG0EK-hcCdPQTYz8d4xm7jTHXDI5B2J5Tbo9knWcawPkXyrdaoVXdvWEacIjwM9p4JFXXTHoFlwwUrWZXVgagCuYsfBvNADAwQxPhUeeNOOh-4YRwHOAoFADXxspHQHmNl8vqavPNsd5JkQCc82z_2_1c3IXf6GnB2NbZHPx9cK8AAC50C-thoAjn3I4ZkO4vrV78H40hvObvfHk408lf3b8 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEJcXBOVWGGAk2NOyxXYSxw8IoY6pZeuYxDb1zdixIzqNdJBuqPwB_g2_kWPn0o3LxsueGtU-cRwfn_Od-FwQeqFjY1IqdGCUYEGkkiwAO4QHKtYJVxnhWrnY4eF20t-L3o3i0QL62cTCOLfKRiZ6QW0mmftGvkaTmDPQ90n4-uhL4KpGudPVpoRGxRabdvYNTLby1WAd1vclpRtvd3v9oK4qEGTA3dOA5gIsMJUzeIeZyGESYayBazU0cJNYdzRpckuYESn8qNSEnKdaK0qUCknO4L5X0NWIwdZ0kem9Uy4lzBcSAbMmCiISjuYRQ2sHqycqc0flYJJS6rOrMvYvXfgn1v3dZfOUDty4jW7V4BW_qbjtDlqwRQddq8pZzjro-rA-qO-g5Z0qJfZsBe_OI7zKFbyMd-bJsoGms-_8cXxQMG7I76IflasuHhe4cjipZTKe5PCfi8U4AYxs4NqXWPmucD1vR9HEp2M9wyAtsQ9c8fcqXboq7D6Lwl7D488-bGZqD2dYWwDvFgMaxr33-4P1gAgMj30P7V3K4t5Hi8WksA8RVpEFy0OZ0NLMGcFaEEM4A8CUJDzMbRdFzeLJrM6n7sp6HMrGce5A1nOXbs1lGElY8y5abcmOqoQiFxEkDWfIJloW5LsElXcRIf8boS1rKVVKIkvoLD-EHhWHI-pEZiRoF6UtZQ3EKoD1P4MuNcwr23Hme7eLnrfNIMfc4ZQq7OTY9wFo5LIjntcHwD6Y_InoogfVfmjfIQNTAOAujMDP7JS2g8ujfralGH_y-dRTIWLQa4_Of_Rn6EZ_d7gltwbbm4_RTTdn50VCyBJanH49tk8AnE71Uy8RMPp42SLoF76Spq4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEBMvCMotMMBIsKdljeMkjh8QQi3VytioxDb1zbNjR3Qa6SDdUPkD_Cd-HcfOpRuXjZc9Nap94jg-Puc78bkg9ELFWqchV76WnPqRTDIf7BDmy1glTGaEKWljh7d3ks296N04Hi-hn00sjHWrbGSiE9R6mtlv5N0wiRkFfZ8E3bx2ixj1B6-Pv_i2gpQ9aW3KaVQssmXm38B8K18N-7DWL8Nw8Ha3t-nXFQb8DDh95oc5B2tM5hTeZ8ZzmFAQK-BgBQ1MJ8YeU-rcEKp5Cj8y1QFjqVIyJFIGJKdw32voOqMstXss7Z1xL6GuqAiYOJEfkWC8iB7qHm6cyswem4N5GoYu0yql_9KLf-Le3903z-jDwW10qway-E3FeXfQkik66EZV2nLeQSvb9aF9B62NqvTY83W8u4j2KtfxGh4tEmcDTWff-ua4AGHckN9FPyq3XTwpcOV8UstnPM3hPxuXcQp4WcO1K7fyXeJ63paiiVXHao5BcmIXxOLuVdrUVdh-IoV9hyefXQjNzBzNsTIA5A0GZIx7H_aHfZ9wDI99D-1dyeLeR8vFtDAPEZaRAStE6sCEmTWIFSeaMArgKUlYkBsPRc3iiazOrW5LfByJxonuUNRzF3bNRRAJWHMPbbRkx1VykcsIkoYzRBM5C7JegPq7jJD9jdCUtcQqBREldBYfA4eQg3FoxWfEQw-lLWUNyiqw9T-DrjbMK9pxFvvYQ8_bZpBp9qBKFmZ64voATLKZEi_qA8AfzP-Ee-hBtR_ad0jBLADoCyOwczul7WBzqp9vKSafXG71lPMYdNyjix_9GVoB4SPeD3e2HqObdsrWoYSQVbQ8-3pingBOnamnTiBgdHDVEugXba2q5A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+in+effectiveness+of+inactivated+influenza+vaccine+in+children+by+age+groups+in+seven+seasons+immediately+before+the+COVID-19+era&rft.jtitle=Vaccine&rft.au=Shinjoh%2C+Masayoshi&rft.au=Furuichi%2C+Munehiro&rft.au=Kobayashi%2C+Hisato&rft.au=Yamaguchi%2C+Yoshio&rft.date=2022-05-11&rft.pub=Elsevier+Ltd&rft.issn=0264-410X&rft.volume=40&rft.issue=22&rft.spage=3018&rft.epage=3026&rft_id=info:doi/10.1016%2Fj.vaccine.2022.04.033&rft.externalDocID=S0264410X22004492 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X22X00212%2Fcov150h.gif |